Anal cancer is a form of cancer that starts in the tissues of the anus – the opening through which stool passes out of the body at the end of the digestive tract. It is a rare type of cancer, different from colorectal cancer, which involves the colon or rectum. The anus is the lower end of the gastrointestinal tract, which is made up of different types of tissue: squamous cells, glandular cells and muscle cells. So it is possible for anal cancer to develop from any of these types. The most common type of anal cancer is squamous cell carcinoma, which will develop from the squamous cells that line the anus.
The cells that cause anal cancer are usually those lining the anal canal, this short section of the lower gastrointestinal tract that extends from the rectum to the anus within the body. Waste material from the end of the digestive tract thus passes out through the anus as stool. The lining of this canal contains both squamous cells and glandular cells, each of which has a different function: squamous cells form the outer layer of flat skin and other areas, while glandular cells produce mucus for lubrication of the digestive tract. Thus, anal cancer is relatively rare, but its incidence has been increasing during the past few decades and it is more likely to be diagnosed in selected populations.
Infection with HPV (human papillomavirus) is a risk factor for anal cancer. Human papillomavirus is a collection of viruses that can cause warts and trigger various types of cancer. Most HPV infections are sexually transmitted, and the high-risk types of this virus strongly associated with anal cancer include HPV-16 and HPV-18. These strains induce abnormal activities in the DNA of infected cells and result in overgrowth and tumor formation. By itself, HPV infection is a necessary but not sufficient condition for the development of anal cancer; the inclusion of other risk factors (such as smoking, impaired immune system, and other lifestyle factors) increases the likelihood of developing this disease.
In addition to HPV infection, individuals with weakened immunity are at risk of developing anal cancer, such as people with HIV/AIDS, organ transplant recipients, or individuals taking immunosuppressive medications. For example, compared to the general population, anal cancer is highly prevalent in HIV-positive individuals because the weakened immune system is less able to control HPV infection. It has been found that antiretroviral therapy (ART) reduces the incidence of anal cancer in HIV patients, although they are still at a higher risk than HIV-negative individuals. Some known risk factors that may increase a person's risk of developing anal cancer include a history of anal or genital warts, multiple sexual partners, and anal receptive intercourse.
The symptoms associated with anal cancer vary greatly according to the stage of the disease and the location of the tumor. This is because in the early stages of anal cancer, there are no noticeable symptoms, and hence this cancer is diagnosed at a later stage. The most common symptoms usually include rectal bleeding, anal pain or discomfort, anal itching, development of an anal mass or lump outside or inside the anus, change in bowel habit, and a feeling of incomplete defecation. However, these symptoms can also arise due to other conditions such as hemorrhoids, anal fissures, or inflammatory bowel disease. Hence such symptoms will not fall under the symptoms of cancer.
Diagnosing anal cancer will require a thorough diagnostic workup. A physical examination, digital rectal examination (DRE), anoscopy (examination of the anus with a special instrument called an anoscope), and biopsy are examples of diagnostic tests. Biopsy is known as taking samples of the suspected tumor, removing small tissues and examining them under a microscope to test for signs of cancer. Sometimes imaging tests may be used, such as a CT scan, MRI scan, or PET scan, to find out how far the cancer has spread and whether it has gone to nearby lymph nodes or other organs. The stage of cancer shows how far the disease has spread and has favorable prognosis and treatment options.
There are different treatment approaches for anal cancer depending on the stage of the disease, the location of the tumor, and the overall health of the patient. Typically, anal cancer is treated by surgery, radiation therapy, and chemotherapy combined together. The aim of the treatment is to remove or destroy the cancerous growth, prevent the cancer from metastasizing to other tissues, and increase the patient's chances of survival. Surgery alone is sometimes indicated if the cancer is in the early stages, in which case surgery usually involves removing the tumor as well as a small amount of surrounding tissue. Sometimes, local excision can be performed whereby the tumor will be removed through the anus without a large incision.
When this stage progresses with tumors that have spread to nearby lymph nodes or other sites, specific chemoradiation, which is chemotherapy drug treatment with concomitant radiation therapy, is instituted in anal malignancy. Chemotherapy kills cancer cells or inhibits their growth, while radiation therapy destroys the targeted area with high-energy beams. Chemoradiation used through chemoradiation is considered the standard treatment for many anal cancers and has shown effectiveness in increasing survival rates and reducing the incidence of recurrence.
In such advanced cases, or in cases that have failed all other forms of treatment, surgically imposed alterations may mean complete severing of the anal sphincter or most of the rectum. This procedure can lead to a permanent colostomy, a hole created in the abdomen through which waste is expelled from the body. Still, with improvements in chemoradiation therapy, surgery is becoming less necessary for many patients who are able to maintain anal sphincter function while avoiding a colostomy.
The prognosis depends on the stage of diagnosis, the efficiency of treatment and the general condition of the patient. Generally, the prognosis of anal cancer is considered quite good if diagnosed on time and treated with appropriate measures. The five-year survival rate for localized anal cancers (those that do not spread beyond the anus or nearby lymph nodes) was very high as many people enjoy long-term remission. But if the cancer spreads to distant organs such as the liver or lungs, the prognosis becomes bleak as the survival rate drops significantly.
Post-treatment follow-up after anal cancer treatment is important in identifying signs of recurrence and possibly managing long-term post-treatment side effects. This may include regular physical inspections, imaging tests and blood tests for return signs of cancer detection. Other patients may have problems associated with treatment, including bowel and skin changes along with sexual dysfunction as a result of radiation therapy. Psychological support and counseling may also be valuable for patients struggling with the psychosocial effects of cancer-related diagnosis and treatment.
In fact, preventive measures against anal cancer will include measures to reduce the risk of HPV infection, which is the most important factor in its development. Vaccination against HPV, especially through the official HPV vaccine, has proven to be very helpful in preventing infection with the high-risk variants of this virus that are most commonly associated with anal cancer. This vaccine is recommended for men and women before the onset of sexual activity, so ideally before becoming sexually active. Safer sex practices such as condom use can only reduce the risk of transmission to some extent but cannot guarantee 100% protection.
However, in addition to HPV prevention, certain lifestyle changes such as stopping smoking and keeping one's immune system healthy can help reduce the risk of anal cancer. Smoking is a known risk for various cancers, including anal cancer. Quitting greatly reduces the chances of anal cancer. People with HIV or other immune deficiency conditions will benefit from close collaboration with their health care providers in considering risk factors in the management and prevention of anal cancer.
Anal cancer is quite rare and yet serious, and can prove fatal in the absence of early detection and treatment. Anal cancer is associated with infection with high-risk types of HPV and is also primarily associated with immune compromise, which significantly increases a person's chances of developing the disease. The unfortunate part is that the symptoms of anal cancer are very similar to other anal diseases, making it almost impossible to detect it early. However, with advances in treatment, especially with chemoradiation, many anal cancer patients are now able to live long lives with normal bowel function. Prevention through vaccination for HPV and safe sex practices can reduce the risk of anal cancer, and frequent screening of high-risk individuals can detect this deadly disease early, when treatment is most effective.
